Septerna Inc (SEPN) Stock Price, Quote & News

Company Profile

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 338 3533

Website: septerna.com

Address:

250 East Grand Avenue, South San Francisco, United States

DCRMIA Oct. 5 at 3:14 PM

$SEPN is doing great!

0 · Reply

Vikingsstrade Oct. 3 at 4:42 PM

$SEPN $CNTX $LITM $LENZ Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.

0 · Reply

BillRayValentine Sep. 29 at 4:31 PM

$SEPN What Studd of a stock. Let's Phuking Go!! Check the date..😎🤑🙏🏿✊🏿🤑🤑🙏🏿 Cuey celebration gif...

0 · Reply

GfromTn Sep. 21 at 11:47 PM

$SEPN we are positioned very well and we have a tremendously strong team so this week looking for $18 and 22-28 eoy

0 · Reply

222short222 Sep. 19 at 12:32 PM

$SEPN

0 · Reply

Trader1141 Sep. 19 at 10:53 AM

$SEPN another $ATMV 😍

0 · Reply

BillRayValentine Sep. 18 at 2:59 PM

$SEPN Beautiful 😍👍🏿🙏🏿🤑

0 · Reply

BillRayValentine Sep. 15 at 7:55 PM

$SEPN This thing is a Horse. I'm still ridin. Gonna ride right into $16 plus. 🙏🏿🦾😎

0 · Reply

GfromTn Sep. 12 at 12:30 PM

$SEPN $15 break and end of this year we will see $20’s this one is only getting better and better been holding and will continue to hold for when this runs

0 · Reply

BillRayValentine Sep. 11 at 2:20 PM

$SEPN I tried to tell y'all in the $9's!! Now it's about to get stank in here!! 😩👊🏿🙌🏿🙏🏿🌛

0 · Reply

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

Septerna to Participate in Upcoming Investor Conferences

Aug 21, 2025, 8:00 AM EDT - 6 weeks ago

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

Aug 11, 2025, 4:01 PM EDT - 2 months ago

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Jun 23, 2025, 2:30 PM EDT - 3 months ago

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

May 29, 2025, 8:00 AM EDT - 4 months ago

Septerna to Present at Jefferies Global Healthcare Conference

May 16, 2025, 4:32 PM EDT - 5 months ago

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

May 16, 2025, 11:50 AM EDT - 5 months ago

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

NVO

May 15, 2025, 4:01 PM EDT - 5 months ago

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

May 14, 2025, 9:43 AM EDT - 5 months ago

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

NVO

May 14, 2025, 7:31 AM EDT - 5 months ago

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

NVO

May 14, 2025, 7:04 AM EDT - 5 months ago

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

NVO

May 14, 2025, 6:59 AM EDT - 5 months ago

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Mar 31, 2025, 2:34 PM EDT - 6 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CRVO CVS GERN LLY NVO

Mar 27, 2025, 8:00 AM EDT - 6 months ago

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 10:32 AM EDT - 7 months ago

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

Mar 6, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Shareholders to Reach Out

Mar 5, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Shareholders to Learn More About the Investigation

Mar 4, 2025, 10:00 AM EST - 7 months ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 3, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Shareholders to Inquire about Securities Investigation

Mar 2, 2025, 10:00 AM EST - 7 months ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 28, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Septerna, Inc. (SEPN) And Encourages Investors to Connect

Feb 27, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Stockholders to Inquire about Securities Investigation

Feb 26, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Investors to Learn More About the Investigation

Feb 26, 2025, 8:00 AM EST - 7 months ago

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 10:00 AM EST - 8 months ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Stockholders to Learn More About the Investigation

Feb 21, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation

Feb 20, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Investors to Reach Out

Feb 19, 2025, 2:00 PM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out

Feb 18, 2025, 4:15 PM EST - 8 months ago

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Feb 18, 2025, 8:00 AM EST - 8 months ago

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Dec 18, 2024, 8:00 AM EST - 10 months ago

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 7:00 AM EST - 11 months ago

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 19, 2024, 2:10 PM EST - 11 months ago

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

Oct 30, 2024, 4:41 PM EDT - 1 year ago

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

Oct 26, 2024, 1:30 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

INGM LBGJ PRB ROLR SNYR

Oct 25, 2024, 12:25 PM EDT - 1 year ago

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Oct 24, 2024, 9:47 PM EDT - 1 year ago

Septerna Prices Upsized Initial Public Offering

Oct 24, 2024, 8:11 AM EDT - 1 year ago

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

Oct 21, 2024, 6:26 AM EDT - 1 year ago

Biotech Septerna aims to raise up to $186 million in US IPO

Oct 7, 2024, 11:36 AM EDT - 1 year ago

Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline

DCRMIA Oct. 5 at 3:14 PM

$SEPN is doing great!

0 · Reply

Vikingsstrade Oct. 3 at 4:42 PM

0 · Reply

BillRayValentine Sep. 29 at 4:31 PM

$SEPN What Studd of a stock. Let's Phuking Go!! Check the date..😎🤑🙏🏿✊🏿🤑🤑🙏🏿 Cuey celebration gif...

0 · Reply

GfromTn Sep. 21 at 11:47 PM

$SEPN we are positioned very well and we have a tremendously strong team so this week looking for $18 and 22-28 eoy

0 · Reply

222short222 Sep. 19 at 12:32 PM

$SEPN

0 · Reply

Trader1141 Sep. 19 at 10:53 AM

$SEPN another $ATMV 😍

0 · Reply

BillRayValentine Sep. 18 at 2:59 PM

$SEPN Beautiful 😍👍🏿🙏🏿🤑

0 · Reply

BillRayValentine Sep. 15 at 7:55 PM

$SEPN This thing is a Horse. I'm still ridin. Gonna ride right into $16 plus. 🙏🏿🦾😎

0 · Reply

GfromTn Sep. 12 at 12:30 PM

$SEPN $15 break and end of this year we will see $20’s this one is only getting better and better been holding and will continue to hold for when this runs

0 · Reply

BillRayValentine Sep. 11 at 2:20 PM

$SEPN I tried to tell y'all in the $9's!! Now it's about to get stank in here!! 😩👊🏿🙌🏿🙏🏿🌛

0 · Reply

JarvisFlow Sep. 5 at 1:52 PM

Cantor Fitzgerald has adjusted their stance on Septerna ( $SEPN ), setting the rating to Overweight with a target price of 25.

0 · Reply

BigSqueezeComing Sep. 5 at 1:39 PM

$SCAG added more shares to $SEPN.

0 · Reply

BillRayValentine Sep. 3 at 6:47 PM

$SEPN 🥰🤑🙏🏿

0 · Reply

habesha_kingtchalla Aug. 25 at 4:08 PM

$SEPN

0 · Reply

_Julia Aug. 24 at 3:57 PM

$SEPN What's up guys. I founded this board. Hope you are doing well. Good luck 🤞

1 · Reply

DCRMIA Aug. 22 at 11:08 AM

$SEPN "H.C. Wainwright Reiterates Buy Rating on Septerna Inc" https://www.investing.com/news/pro/hc-wainwright-maintains-septerna-at-buy-with-a-price-target-of-2600-4206519

0 · Reply

SocioCobb Aug. 14 at 12:56 AM

$SEPN 5 month 2 banger

0 · Reply

kuwshlavi Aug. 13 at 3:46 PM

$SEPN 👀👀

0 · Reply

DCRMIA Aug. 13 at 10:35 AM

I am quite optimistic about $SEPN 🚀🚀

1 · Reply

kuwshlavi Aug. 12 at 2:42 PM

$SEPN should be too much money to keep it under $12 we shall see though

0 · Reply

Copperhead_Road Aug. 12 at 2:12 PM

$SEPN take this down to $10 today

0 · Reply

kuwshlavi Aug. 12 at 1:46 PM

$SEPN not doing a pr after closing the Novo deal led to this.. smfh now just a spot on the watchlist

1 · Reply

Market Cap	922.02M
Revenue (ttm)	1.08M
Net Income (ttm)	-71.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,648.15%
Debt to Equity Ratio	0.00

Volume	536,400
Avg Vol	253,184
Day's Range	N/A - N/A
Shares Out	44.59M
Stochastic %K	95%
Beta	N/A
Analysts	Strong Sell
Price Target	$24.25